CHANGE IN RATINGS
downgraded at JP Morgan from Overweight to Neutral. Valuation call, as the stock is up 45% over the past 12 months.
downgraded at KBW to Underperform. $30 price target. Expect stock to suffer as a consumer-led recession is likely to materialize in the US.
downgraded at Morgan Stanley from overweight to equalweight and moves price target from $47 to $56.
upgraded at Keefe, Bruyette & Woods from Market Perform to Outperform. $250 price target. 2008 estimates also raised.
Marshall & Ilsley
( MI) downgraded at Keefe, Bruyette & Woods to Underperform. Stock trades at a 20% premium to its peers, and would be hurt by a consumer-led recession that's likely to materialize.
upgraded at Weisel from Market-weight to Overweight. $30 price target. Stock looks attractive compared with its peers, and should start to receive more credit for its revenue growth.
downgraded at JP Morgan from Overweight to Neutral. Valuation call, as the stock has already gained 50% for the year. Company remains on track for 16% earnings growth in 2008.
upgraded at Jefferies to Buy rating from Hold. Price target jumps to $25 from $18.50 and FY 2008 eps estimates upped to $0.91 from $0.87.
downgraded at Goldman Sachs to Neutral from Buy based on continuing negative sentiment and lack of near-term catalysts. Note that stock underperformance has been driven by slower SSS, declining new store productivity, margin erosion, and concerns over U.S. competition and saturation. Price target at $26.
downgraded at Keefe, Bruyette & Woods to Underperform. Estimates also cut, at the US is likely heading into a consumer-led recession.
downgraded at Citigroup from Hold to Sell. $15 price target. Company's desperate measures will further dilute earnings, and limit any potential near-term growth.
STOCK COMMENTS / EPS CHANGES
target price raised at Credit Suisse to $149 from $120. Cites all news on the horizon appears positive and fourth quarter looks very strong. Maintained Outperform rating.
target price reduced at Deutsche Bank from $85 to $69 following capital infusion.
( PLA) numbers lowered at UBS. Price target dips to $11 from $12.50 and FY 2008 eps estimates down to $0.47 from $0.52. Reiterates Neutral rating.
numbers slashed at UBS. FY 2008 eps estimates drop to $(0.05) from $2.75 while holding a price target of $21. Reiterates Neutral rating.